Destiny Pharma says XF-73 now "very well positioned" for a partnering programme
News release
by
Destiny Pharma PLC
London, UK
|
April 18, 2023 09:15 AM Eastern Daylight Time
Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) CEO Neil Clark speaks to Thomas Warner from Proactive after releasing the clinical-stage biotechnology company's full year results for 2022.
Clark says that Destiny Pharma is focused on finding a partner for its lead asset, XF-73, a nasal gel that decolonizes patients before surgery to prevent post-surgical infections.
He adds that the asset is now "very well positioned" for a partnering programme.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
